Rayan Kaedbey

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

Suzanne Trudel, Adam D. Cohen, Amrita Krishnan et al. · Blood · 2021 · 161 citations

Medicine, Pharmacology, Pharmacotherapy +9

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates

Olena Kis, Rayan Kaedbey, Signy Chow et al. · Nature Communications · 2017 · 138 citations · Full text

Medicine, Genetics, Oncology +17

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Alexander M. Lesokhin, Joshua Richter, Suzanne Trudel et al. · Blood · 2022 · 75 citations

Medicine, Oncology, Immunotherapy +10

Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity

Suzanne Trudel, Nizar J. Bahlis, Andrew Spencer et al. · Blood · 2022 · 40 citations

Life Sciences, Immunology, Pharmacotherapy +17

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Joshua Richter, Sheeba K. Thomas, Amrita Krishnan et al. · Blood · 2024 · 29 citations · Full text

Medicine, Oncology, Pharmacology +13